Fortress Diagnostics COVID-19 Rapid Antibody Testing
Rapid antibody testing for SARS-CoV-2 (COVID-19)
As used in the ongoing government funded, Imperial College led REACT surveillance study.
The Fortress COVID-19 Total Antibody Device is a single use, lateral flow device for the qualitative detection of total antibodies against 2019 novel coronavirus (SARS-CoV-2) in human serum, plasma or whole blood specimens.
Una Health and Fortress Diagnostics are partnering with the Department of Health & Social Care in the Real Time Assessment of Community Transmission (REACT) Study into COVID-19. The REACT study is being led by Imperial College London and Ipsos MORI and is looking to understand how many people are currently infected, or have been infected, with the COVID-19 virus. Through the partnership, the Fortress COVID-19 Total Antibody Device has been supplied for the study. The kit demonstrated a specificity of over 98%, which the UK Medicines and Healthcare products Regulatory Agency (MHRA) recommends as the minimum level for use in the clinic.